Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade)
Source: SeekingAlpha
2025-10-13 14:35:33 ET
Shares of mast cell therapy concern Celldex Therapeutics, Inc. ( CLDX ) have rallied just over 70% off their 60-month April 2025 low that was caused by high discontinuation rates for lead asset barzolvolimab. The company’s only significant candidate has demonstrated best-in-class efficacy in chronic spontaneous urticaria, which it is trying to replicate in two Phase 3 studies that are now enrolling. With an operating runway through 2027, good enough to get it through four needle-moving studies in increasingly competitive indications, Celldex merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade)
Celldex Therapeutics Inc.
NASDAQ: CLDX
CLDX Trading
5.31% G/L:
$30.445 Last:
591,333 Volume:
$29.21 Open:
CLDX Latest News
February 27, 2026 02:45:00 pm
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAA
February 25, 2026 04:01:00 pm
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
CLDX Stock Data
$1,661,236,775
63,525,694
0.16%
57
N/A
Biotechnology & Life Sciences
Healthcare
US
Hampton
